Senses Disorder TRIZ Cases

This case uses targeted IleRS inhibition with N-acyl-arylsulfonamides to develop antibacterial options beyond resistant drugs.

This case combines LB-100 with monosodium glutamate to stabilize a PP2A inhibitor formulation for clinical trials.

Unequal RNA strand lengths support potent, durable gene silencing with fewer off-target and interferon-like responses.

This case uses localized amino acid substitutions to raise PDGF and VEGF receptor affinity while preserving most of the wild-type sequence.

A hydrogen generating system uses moisture to produce gas within a permeable container enclosed by a low-permeability wrapping member.

Developing stable crystalline salts resolves formulation complexity while improving bioavailability and manufacturability.

Merging separate therapies into one molecule eliminates co-administration complexity while maintaining dual pathway inhibition.

Segmented dendrimer surfaces with distinct terminal groups resolve the trade-off between high drug loading capacity and controllable ADME profiles.

Antibodies bind TGFβ isoforms to modulate immune cells, resolving inadequate therapeutic outcomes in cancer and fibrosis.

Nitrogen heterocyclic amino alcohol derivatives quench reactive carbonyl compounds, resisting metabolic degradation to treat oxidative damage disorders.

0.1% cyclosporine dissolved in 1-(perfluorobutyl) pentane provides targeted topical relief for dry eye symptoms.

Intravitreal PEG-G-CSF prevents traumatic optic neuropathy vision loss by inhibiting macrophage infiltration and apoptosis without corticosteroid side effects.

Novel heterocyclyl-substituted cyclohexylmethansulfonamide compounds inhibit Janus kinase enzymes to treat inflammatory skin conditions.

ERβ-selective ligands resolve the contradiction between therapeutic benefit and harmful side effects by targeting specific receptor isoforms.

Recombinant adeno-associated virus vector delivers nanobody gene encoding anti-VEGF protein to reduce treatment frequency and cost for wet AMD.

Compatible solute agents stimulate uptake and retention in ocular surface cells to enhance protection against hypertonicity.

Pyrimidone derivatives inhibit GSK3β enzyme activity to treat neurodegenerative diseases.

A non-micellar iron-casein complex protects sensitive compounds from oxidation while maintaining high bioavailability.

Nicotinamide riboside increases intracellular NAD+ levels to suppress oxidative damage and activate SIRT3, preventing noise-induced synaptic disruption.

Retinoid compounds stabilize mutant opsin proteins via partial inhibition of 11-cis-retinal binding, reducing toxic visual cycle product accumulation.

Diazeniumdiolate derivatives merge diuretic and nitric oxide donor functions to treat hypertension while reducing endothelial dysfunction.

Converting N-acylethanolamide to prodrugs via phosphate or sucrose conjugation overcomes poor oral bioavailability and low target site exposure.

Tacrolimus combined with semifluorinated alkanes treats intraocular inflammation via topical delivery.

Compartmentalizing samples into microfluidic droplets with a gel-forming agent to isolate and detect aggregatory seeds.

Modified Anc80 capsid proteins enable efficient gene delivery to cochlear cells, resolving low transduction rates in genetic hearing loss therapies.

A transdermal prostaglandin E1 patch delivers the drug through skin permeation to increase ocular blood flow.

Systematic parameter changes in pyrrolo[2,3-d]pyrimidine cores improve solubility and reduce adverse side effects while maintaining high inhibitory activity.

Deuterated NACA-d3 and diNACA-d6 scavenge free radicals to halt disease progression in retinitis pigmentosa.

Segmenting the oversized PCDH15 gene into two AAV vectors enables trans splicing in target cells, restoring hearing and vision in Usher syndrome models.

Saposin B binds the bisretinoid A2E to prevent its degradation, reducing accumulation that drives macular degeneration.

Suprachoroidal nitric oxide delivery increases choroidal blood flow while avoiding systemic side effects from oral administration.

Sucrose octasulfate inhibits hyaluronidases to preserve hyaluronic acid viscosity and extend gel persistence.

Locked nucleic acid monomers stabilize siRNA duplex structures to enhance biostability and cellular uptake efficiency.

Surfactant-loaded contact lenses extend drug release duration by slowing diffusion rates, reducing systemic absorption and wastage.

Modifying the alpha-carbon of the three-position amino acid reduces epimerization rates in methanolic solutions, extending shelf life for dry eye treatments.

Ionic emulsifiers solubilize resveratrol in omega-3 fatty acids, avoiding lengthy microencapsulation processes.

Lactobacillus plantarum PL-02 strain composition repairs retinal damage caused by blue light irradiation.

Compressed fluid technology synthesizes stable EGF vesicles, eliminating solvent use and improving reproducibility.

A filtered seawater aqueous composition enriched with specific potassium and zinc concentrations targets ocular surface tissues.

Specific 4' substituents on Formula I retinoids reduce glucuronidation rates to improve drug stability while maintaining tumor selectivity.

Genetic screening identifies CFD variant nucleic acids to prevent unnecessary inhibitor administration in low-risk patients.

Anchoring therapeutic proteins to Type II collagen extends half-life, reducing injection frequency for neovascular eye diseases.

Pyrazolo pyridine derivatives inhibit NADPH oxidase activity to reduce reactive oxygen species production.

Pyrrolidinyl urea compounds selectively inhibit TrkA kinase, blocking NGF signaling to relieve severe pain without opioid addiction or respiratory depression.

Hyperpolarizing horizontal cells via nucleic acids shifts rod photoreceptor sensitivity, resolving contrast encoding limits in retinal degeneration.

A dose unit with a heating element vaporizes isolated bioactive agents on a carrier material for pulmonary delivery.

Biodegradable polymer implants encapsulate therapeutic proteins to maintain stable vitreal concentrations and reduce injection frequency.